Amarin PLC Operating Income Over Time
| AMRN Stock | USD 15.63 0.04 0.26% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Amarin PLC Performance and Amarin PLC Correlation. Will Biotechnology sector continue expanding? Could Amarin diversify its offerings? Factors like these will boost the valuation of Amarin PLC. If investors know Amarin will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Amarin PLC data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth (0.94) | Earnings Share (4.20) | Revenue Per Share | Quarterly Revenue Growth 0.174 | Return On Assets |
Understanding Amarin PLC requires distinguishing between market price and book value, where the latter reflects Amarin's accounting equity. The concept of intrinsic value - what Amarin PLC's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Amarin PLC's price substantially above or below its fundamental value.
Understanding that Amarin PLC's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Amarin PLC represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Amarin PLC's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Operating Income Analysis
Compare Amarin PLC and related stocks such as Silence Therapeutics PLC, Alto Neuroscience, and AC Immune Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SLN | (933 K) | (5.8 M) | (26.3 M) | (9.1 M) | (12.1 M) | (9.8 M) | (11.9 M) | (14.4 M) | (20.6 M) | (22.7 M) | (35.8 M) | (45.8 M) | (61 M) | (49.6 M) | (63.3 M) | (57 M) | (54.1 M) |
| ANRO | (12.1 M) | (12.1 M) | (12.1 M) | (12.1 M) | (12.1 M) | (12.1 M) | (12.1 M) | (12.1 M) | (12.1 M) | (12.1 M) | (12.1 M) | (29.2 M) | (37.8 M) | (68.6 M) | (68.6 M) | (61.7 M) | (58.7 M) |
| ACIU | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | 10.7 M | 18.6 M | (10.5 M) | (22.5 M) | (49.5 M) | 44.5 M | (61.3 M) | (79 M) | (70.8 M) | (53.6 M) | (52.4 M) | (47.1 M) | (44.8 M) |
| CLLS | (7.8 M) | (25.3 M) | (26.1 M) | (80.6 M) | (6.4 M) | (30.5 M) | (64 M) | (92.7 M) | (105.1 M) | (123.6 M) | (85.4 M) | (85.4 M) | (89.7 M) | (97.3 M) | (59.6 M) | (53.6 M) | (56.3 M) |
| LRMR | (13.2 M) | (13.2 M) | (13.8 M) | (13.8 M) | (35.5 M) | (73.8 M) | (57.1 M) | (53.9 M) | (62.7 M) | (23.2 M) | (42.8 M) | (50.5 M) | (36.5 M) | (41.8 M) | (90.9 M) | (81.8 M) | (77.7 M) |
| KRRO | (16.3 M) | (16.3 M) | (16.3 M) | (16.3 M) | (16.3 M) | (16.3 M) | (16.3 M) | (16.3 M) | (18.9 M) | (20.7 M) | (27.6 M) | (84 M) | (59 M) | (84.5 M) | (91.9 M) | (82.7 M) | (78.6 M) |
| DBVT | (7.5 M) | (9.4 M) | (17.7 M) | (27.5 M) | (29.8 M) | (54.3 M) | (122.1 M) | (173.9 M) | (190.1 M) | (171 M) | (158.8 M) | (98.6 M) | (96.6 M) | (76.4 M) | (120.5 M) | (108.5 M) | (113.9 M) |
| ALT | 325.3 K | (11.7 M) | (6.3 M) | (10.8 M) | (10.2 M) | (3.4 M) | (11.3 M) | (52 M) | (42.8 M) | (21.5 M) | (54.8 M) | (96.9 M) | (87.7 M) | (95.9 M) | (103.2 M) | (92.9 M) | (88.2 M) |
| LYEL | (102.1 M) | (102.1 M) | (102.1 M) | (102.1 M) | (102.1 M) | (102.1 M) | (102.1 M) | (102.1 M) | (102.1 M) | (102.1 M) | (211.9 M) | (214.8 M) | (187.1 M) | (247 M) | (358.8 M) | (322.9 M) | (339 M) |
Amarin PLC and related stocks such as Silence Therapeutics PLC, Alto Neuroscience, and AC Immune Operating Income description
Operating Income is the amount of profit realized from Amarin PLC operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Amarin PLC is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Amarin PLC | AMRN |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | One Central Plaza, |
| Exchange | NASDAQ Exchange |
USD 15.63
Check out Amarin PLC Performance and Amarin PLC Correlation. To learn how to invest in Amarin Stock, please use our How to Invest in Amarin PLC guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Amarin PLC technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.